Ingersoll Rand acquires Scinomix to enhance life sciences capabilities, improving automation and workflow solutions.
Quiver AI Summary
Ingersoll Rand Inc. has announced its acquisition of Scinomix, Inc., a U.S.-based company that specializes in automation technologies for life sciences, enhancing Ingersoll Rand's portfolio and supporting its growth strategy. This acquisition is expected to streamline workflow automation and improve efficiency and accuracy for customers in various sectors like clinical and pharmaceutical labs, among others. By integrating Scinomix's innovative solutions with its existing technologies, Ingersoll Rand aims to offer comprehensive end-to-end solutions in laboratory environments. The acquisition highlights Ingersoll Rand’s capability to identify strategic, founder-owned companies for growth and was made at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA. CEO Vicente Reynal expressed enthusiasm for the added expertise and potential this acquisition brings to the company's mission.
Potential Positives
- Bolt-on acquisition enhances Ingersoll Rand’s growth strategy by providing scalable opportunities for innovation and market expansion within life sciences.
- The acquisition allows Ingersoll Rand to offer more comprehensive solutions through advanced technologies that improve automation and accuracy for customers.
- By adding Scinomix to its portfolio, Ingersoll Rand demonstrates its capability to identify and cultivate strategic acquisitions, further strengthening its market position.
- The investment was made at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA, indicating a favorable financial decision for the company.
Potential Negatives
- Concerns regarding the uncertainty of achieving expected financial performance and synergies from the acquisition, which could negatively impact operational results.
- The acquisition highlights potential risks of unexpected costs or charges associated with integrating Scinomix into Ingersoll Rand's operations.
- The press release emphasizes significant reliance on forward-looking statements, which may lead to volatility in market perception and investor confidence if anticipated outcomes are not met.
FAQ
What is the purpose of Ingersoll Rand's acquisition of Scinomix?
The acquisition supports Ingersoll Rand's growth strategy by enhancing automation solutions within the life sciences sector.
How will the acquisition of Scinomix benefit Ingersoll Rand customers?
Customers will gain access to comprehensive, innovative solutions that streamline workflows and increase accuracy in lab environments.
What technologies does Scinomix specialize in?
Scinomix specializes in automation technologies, including labeling, handling, barcode scanning, and capping for various lab equipment.
What segment will Scinomix join within Ingersoll Rand?
Scinomix will join the Life Sciences platform within the Precision and Science Technologies (P&ST) segment of Ingersoll Rand.
What is the purchase multiple for the Scinomix acquisition?
The acquisition was made at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IR Insider Trading Activity
$IR insiders have traded $IR stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $IR stock by insiders over the last 6 months:
- MICHAEL J SCHESKE (VP, Chief Accounting Officer) sold 1,477 shares for an estimated $119,086
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IR Revenue
$IR had revenues of $2B in Q3 2025. This is an increase of 5.05% from the same period in the prior year.
You can track IR financials on Quiver Quantitative's IR stock page.
$IR Hedge Fund Activity
We have seen 361 institutional investors add shares of $IR stock to their portfolio, and 397 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 7,816,194 shares (+18.5%) to their portfolio in Q3 2025, for an estimated $645,773,948
- JPMORGAN CHASE & CO removed 5,757,338 shares (-31.6%) from their portfolio in Q3 2025, for an estimated $475,671,265
- PRICE T ROWE ASSOCIATES INC /MD/ removed 5,440,462 shares (-28.1%) from their portfolio in Q3 2025, for an estimated $449,490,970
- CAPITAL WORLD INVESTORS added 5,110,668 shares (+19.2%) to their portfolio in Q3 2025, for an estimated $422,243,390
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 5,066,086 shares (+94.9%) to their portfolio in Q3 2025, for an estimated $418,560,025
- CAPITAL RESEARCH GLOBAL INVESTORS added 2,406,183 shares (+14.3%) to their portfolio in Q3 2025, for an estimated $198,798,839
- BLACKROCK, INC. removed 2,136,267 shares (-6.7%) from their portfolio in Q3 2025, for an estimated $176,498,379
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IR Analyst Ratings
Wall Street analysts have issued reports on $IR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 11/03/2025
- Citigroup issued a "Buy" rating on 11/03/2025
- Wells Fargo issued a "Overweight" rating on 10/06/2025
To track analyst ratings and price targets for $IR, check out Quiver Quantitative's $IR forecast page.
$IR Price Targets
Multiple analysts have issued price targets for $IR recently. We have seen 6 analysts offer price targets for $IR in the last 6 months, with a median target of $92.5.
Here are some recent targets:
- Nathan Jones from Stifel set a target price of $81.0 on 12/16/2025
- Andrew Kaplowitz from Citigroup set a target price of $94.0 on 12/08/2025
- Michael Halloran from Baird set a target price of $100.0 on 11/03/2025
- Joseph O'Dea from Wells Fargo set a target price of $95.0 on 10/06/2025
- Chris Snyder from Morgan Stanley set a target price of $85.0 on 08/13/2025
- Julian Mitchell from Barclays set a target price of $91.0 on 08/04/2025
Full Release
- Bolt-on acquisition supports the company’s growth strategy with scalable opportunities for innovation and market expansion within life sciences
- Enables Ingersoll Rand to provide more comprehensive solutions using technologies that help streamline workflows with greater automation and increased accuracy for customers
- Adds another founder-owned company to the Ingersoll Rand portfolio and highlights the ability to identify and cultivate acquisitions on a proprietary basis
-
Investment made at attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA
DAVIDSON, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ingersoll Rand Inc., (NYSE: IR) a global provider of mission-critical flow creation and life science and industrial solutions, has acquired Scinomix, Inc., expanding the company’s life sciences portfolio.
Based in the United States, Scinomix designs and manufactures technologies that help streamline automation workflows to drive throughput, accuracy, and traceability across many industries including clinical, pharmaceutical, biotechnology, forensic, agricultural, and genetic testing labs. The company specializes in labeling, handling, barcode scanning, and capping of lab equipment such as tubes, vials, microplates, and liquids.
These types of innovative solutions are used to improve sample management through scalable, easily configurable solutions that enhance efficiency and precision throughout various workflows. The acquisition will enable Ingersoll Rand to combine several existing technologies with Scinomix’s offerings to provide comprehensive, end-to-end solutions in lab environments. Scinomix will join the Life Sciences platform within the Precision and Science Technologies (P&ST) segment.
“We are expanding our portfolio of innovative solutions and opening new opportunities with the acquisition of Scinomix,” said Vicente Reynal, chairman and chief executive officer of Ingersoll Rand. “Their expertise in automation technologies within life sciences strategically complements existing capabilities at Ingersoll Rand, enabling us to better serve our customers. We look forward to welcoming the Scinomix team to the Ingersoll Rand family.”
About Ingersoll Rand Inc.
Ingersoll Rand Inc. (NYSE: IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to Making Life Better for our employees, customers, shareholders, and planet. Customers lean on us for exceptional performance and durability in mission-critical flow creation and life science and industrial solutions. Supported by over 80+ respected brands, our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity, and efficiency. For more information, visit IRCO.com .
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the expectations of Ingersoll Rand Inc. (the “Company” or “Ingersoll Rand”), regarding the performance of its business, its financial results, its liquidity and capital resources and other non-historical statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “will be,” “on track to,” “will continue,” “will likely result,” “guidance” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements other than historical facts are forward-looking statements.
These forward-looking statements are based on Ingersoll Rand’s current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from these current expectations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates, or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) adverse impact on our operations and financial performance due to geopolitical tensions, natural disaster, catastrophe, cyber events, or other events outside of our control; (2) unexpected costs, charges, or expenses resulting from completed and proposed business combinations; (3) uncertainty of the expected financial performance of the Company; (4) failure to realize the anticipated benefits of completed and proposed business combinations; (5) the ability of the Company to implement its business strategy; (6) difficulties and delays in achieving revenue and cost synergies; (7) inability of the Company to retain and hire key personnel; (8) evolving legal, regulatory, and tax regimes; (9) changes in general economic and/or industry specific conditions; (10) actions by third parties, including government agencies; and (11) other risk factors detailed in Ingersoll Rand’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), as such factors may be updated from time to time in its periodic filings with the SEC, which are available on the SEC’s website at http://www.sec.gov . The foregoing list of important factors is not exclusive.
Any forward-looking statements speak only as of the date of this release. Ingersoll Rand undertakes no obligation to update any forward-looking statements, whether as a result of new information or developments, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Contacts:
Investor Relations:
[email protected]
Media:
[email protected]